Stock Track | Jazz Pharmaceuticals Plummets 6.16% as Q1 Earnings Fall Short of Estimates

Stock Track

May 07, 2025

Jazz Pharmaceuticals PLC (JAZZ) saw its stock price plummet 6.16% in Tuesday's trading session following the release of its first-quarter 2025 financial results, which significantly missed analyst expectations across key metrics.

The biopharmaceutical company reported Q1 revenue of $897.841 million, falling short of the IBES estimate of $985.4 million. Adjusted earnings per share (EPS) came in at $1.68, well below the expected $4.66. The company's adjusted net income for the quarter was $105.233 million, considerably lower than the estimated $288.6 million. Jazz Pharmaceuticals also reported a net loss of $92.541 million, translating to a loss per share of $1.52.

In light of these disappointing results, Jazz Pharmaceuticals announced updates to its 2025 financial guidance, though specific details were not immediately available. Investors and analysts will likely be closely monitoring the company's future outlook and potential strategies to improve performance in the coming quarters.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1156613132"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1156613132\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1156613132?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-07 04:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1156613132","market":"us","top_or_hot":-1,"title":"Stock Track | Jazz Pharmaceuticals Plummets 6.16% as Q1 Earnings Fall Short of Estimates","media":"Stock Track","content":"<p>Jazz Pharmaceuticals PLC (JAZZ) saw its stock price plummet 6.16% in Tuesday's trading session following the release of its first-quarter 2025 financial results, which significantly missed analyst expectations across key metrics.</p>\n\n<p>The biopharmaceutical company reported Q1 revenue of $897.841 million, falling short of the IBES estimate of $985.4 million. Adjusted earnings per share (EPS) came in at $1.68, well below the expected $4.66. The company's adjusted net income for the quarter was $105.233 million, considerably lower than the estimated $288.6 million. Jazz Pharmaceuticals also reported a net loss of $92.541 million, translating to a loss per share of $1.52.</p>\n\n<p>In light of these disappointing results, Jazz Pharmaceuticals announced updates to its 2025 financial guidance, though specific details were not immediately available. Investors and analysts will likely be closely monitoring the company's future outlook and potential strategies to improve performance in the coming quarters.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Jazz Pharmaceuticals Plummets 6.16% as Q1 Earnings Fall Short of Estimates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Jazz Pharmaceuticals Plummets 6.16% as Q1 Earnings Fall Short of Estimates\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-05-07 04:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Jazz Pharmaceuticals PLC (JAZZ) saw its stock price plummet 6.16% in Tuesday's trading session following the release of its first-quarter 2025 financial results, which significantly missed analyst expectations across key metrics.</p>\n\n<p>The biopharmaceutical company reported Q1 revenue of $897.841 million, falling short of the IBES estimate of $985.4 million. Adjusted earnings per share (EPS) came in at $1.68, well below the expected $4.66. The company's adjusted net income for the quarter was $105.233 million, considerably lower than the estimated $288.6 million. Jazz Pharmaceuticals also reported a net loss of $92.541 million, translating to a loss per share of $1.52.</p>\n\n<p>In light of these disappointing results, Jazz Pharmaceuticals announced updates to its 2025 financial guidance, though specific details were not immediately available. Investors and analysts will likely be closely monitoring the company's future outlook and potential strategies to improve performance in the coming quarters.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"JAZZ","symbol_name":"爵士制药","start_time":0,"source_url":"","article_id":"1156613132","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1156613132","pubTimestamp":1746561995,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Jazz Pharmaceuticals PLC  saw its stock price plummet 6.16% in Tuesday's trading session following the release of its first-quarter 2025 financial results, which significantly missed analyst expectations across key metrics.The biopharmaceutical company reported Q1 revenue of $897.841 million, falling short of the IBES estimate of $985.4 million. Adjusted earnings per share  came in at $1.68, well below the expected $4.66. The company's adjusted net income for the quarter was $105.233 million, co","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"JAZZ":"爵士制药"},"translate_title":"Jazz Pharmaceuticals第一季度盈利低于预期，股价暴跌6.16%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"JAZZ":1},"content_text":"Jazz Pharmaceuticals PLC (JAZZ) saw its stock price plummet 6.16% in Tuesday's trading session following the release of its first-quarter 2025 financial results, which significantly missed analyst expectations across key metrics.\nThe biopharmaceutical company reported Q1 revenue of $897.841 million, falling short of the IBES estimate of $985.4 million. Adjusted earnings per share (EPS) came in at $1.68, well below the expected $4.66. The company's adjusted net income for the quarter was $105.233 million, considerably lower than the estimated $288.6 million. Jazz Pharmaceuticals also reported a net loss of $92.541 million, translating to a loss per share of $1.52.\nIn light of these disappointing results, Jazz Pharmaceuticals announced updates to its 2025 financial guidance, though specific details were not immediately available. Investors and analysts will likely be closely monitoring the company's future outlook and potential strategies to improve performance in the coming quarters.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}